Global Chronic Spontaneous Urticaria Supply, Demand and Key Producers, 2023-2029

March 2023 | 124 pages | ID: GD30168582EAEN
GlobalInfoResearch

Abstracts

The global Chronic Spontaneous Urticaria market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Chronic Spontaneous Urticaria demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Chronic Spontaneous Urticaria, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Chronic Spontaneous Urticaria that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Chronic Spontaneous Urticaria total market, 2018-2029, (USD Million)

Global Chronic Spontaneous Urticaria total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Chronic Spontaneous Urticaria total market, key domestic companies and share, (USD Million)

Global Chronic Spontaneous Urticaria revenue by player and market share 2018-2023, (USD Million)

Global Chronic Spontaneous Urticaria total market by Type, CAGR, 2018-2029, (USD Million)

Global Chronic Spontaneous Urticaria total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Chronic Spontaneous Urticaria market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Mylan N. V., Sanofi, GlaxoSmithKline, Bayer, Merck, Aurobindo Pharma, Hikma Pharmaceuticals, WOCKHARDT and AbbVie, Inc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Chronic Spontaneous Urticaria market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Chronic Spontaneous Urticaria Market, By Region:

• United States
• China
• Europe
• Japan
• South Korea
• ASEAN
• India
• Rest of World

Global Chronic Spontaneous Urticaria Market, Segmentation by Type

• Antihistamine
• Monoclonal Antibody
• Other

Global Chronic Spontaneous Urticaria Market, Segmentation by Application

• Children
• Adult

Companies Profiled:

• Mylan N. V.
• Sanofi
• GlaxoSmithKline
• Bayer
• Merck
• Aurobindo Pharma
• Hikma Pharmaceuticals
• WOCKHARDT
• AbbVie, Inc.
• Cipla Inc.
• F. Hoffmann La Roche Ltd.
• Teva Pharmaceutical Industries, Ltd.
• Pfizer, Inc.
• Novartis AG
• Eli Lilly and Company
• Allergan
• Lupin

Key Questions Answered

1. How big is the global Chronic Spontaneous Urticaria market?

2. What is the demand of the global Chronic Spontaneous Urticaria market?

3. What is the year over year growth of the global Chronic Spontaneous Urticaria market?

4. What is the total value of the global Chronic Spontaneous Urticaria market?

5. Who are the major players in the global Chronic Spontaneous Urticaria market?

6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

1.1 Chronic Spontaneous Urticaria Introduction
1.2 World Chronic Spontaneous Urticaria Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Chronic Spontaneous Urticaria Total Market by Region (by Headquarter Location)
  1.3.1 World Chronic Spontaneous Urticaria Market Size by Region (2018-2029), (by Headquarter Location)
  1.3.2 United States Chronic Spontaneous Urticaria Market Size (2018-2029)
  1.3.3 China Chronic Spontaneous Urticaria Market Size (2018-2029)
  1.3.4 Europe Chronic Spontaneous Urticaria Market Size (2018-2029)
  1.3.5 Japan Chronic Spontaneous Urticaria Market Size (2018-2029)
  1.3.6 South Korea Chronic Spontaneous Urticaria Market Size (2018-2029)
  1.3.7 ASEAN Chronic Spontaneous Urticaria Market Size (2018-2029)
  1.3.8 India Chronic Spontaneous Urticaria Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Chronic Spontaneous Urticaria Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Chronic Spontaneous Urticaria Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
  1.5.1 Influence of COVID-19
  1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

2.1 World Chronic Spontaneous Urticaria Consumption Value (2018-2029)
2.2 World Chronic Spontaneous Urticaria Consumption Value by Region
  2.2.1 World Chronic Spontaneous Urticaria Consumption Value by Region (2018-2023)
  2.2.2 World Chronic Spontaneous Urticaria Consumption Value Forecast by Region (2024-2029)
2.3 United States Chronic Spontaneous Urticaria Consumption Value (2018-2029)
2.4 China Chronic Spontaneous Urticaria Consumption Value (2018-2029)
2.5 Europe Chronic Spontaneous Urticaria Consumption Value (2018-2029)
2.6 Japan Chronic Spontaneous Urticaria Consumption Value (2018-2029)
2.7 South Korea Chronic Spontaneous Urticaria Consumption Value (2018-2029)
2.8 ASEAN Chronic Spontaneous Urticaria Consumption Value (2018-2029)
2.9 India Chronic Spontaneous Urticaria Consumption Value (2018-2029)

3 WORLD CHRONIC SPONTANEOUS URTICARIA COMPANIES COMPETITIVE ANALYSIS

3.1 World Chronic Spontaneous Urticaria Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
  3.2.1 Global Chronic Spontaneous Urticaria Industry Rank of Major Players
  3.2.2 Global Concentration Ratios (CR4) for Chronic Spontaneous Urticaria in 2022
  3.2.3 Global Concentration Ratios (CR8) for Chronic Spontaneous Urticaria in 2022
3.3 Chronic Spontaneous Urticaria Company Evaluation Quadrant
3.4 Chronic Spontaneous Urticaria Market: Overall Company Footprint Analysis
  3.4.1 Chronic Spontaneous Urticaria Market: Region Footprint
  3.4.2 Chronic Spontaneous Urticaria Market: Company Product Type Footprint
  3.4.3 Chronic Spontaneous Urticaria Market: Company Product Application Footprint
3.5 Competitive Environment
  3.5.1 Historical Structure of the Industry
  3.5.2 Barriers of Market Entry
  3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Chronic Spontaneous Urticaria Revenue Comparison (by Headquarter Location)
  4.1.1 United States VS China: Chronic Spontaneous Urticaria Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
  4.1.2 United States VS China: Chronic Spontaneous Urticaria Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Chronic Spontaneous Urticaria Consumption Value Comparison
  4.2.1 United States VS China: Chronic Spontaneous Urticaria Consumption Value Comparison (2018 & 2022 & 2029)
  4.2.2 United States VS China: Chronic Spontaneous Urticaria Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Chronic Spontaneous Urticaria Companies and Market Share, 2018-2023
  4.3.1 United States Based Chronic Spontaneous Urticaria Companies, Headquarters (States, Country)
  4.3.2 United States Based Companies Chronic Spontaneous Urticaria Revenue, (2018-2023)
4.4 China Based Companies Chronic Spontaneous Urticaria Revenue and Market Share, 2018-2023
  4.4.1 China Based Chronic Spontaneous Urticaria Companies, Company Headquarters (Province, Country)
  4.4.2 China Based Companies Chronic Spontaneous Urticaria Revenue, (2018-2023)
4.5 Rest of World Based Chronic Spontaneous Urticaria Companies and Market Share, 2018-2023
  4.5.1 Rest of World Based Chronic Spontaneous Urticaria Companies, Headquarters (States, Country)
  4.5.2 Rest of World Based Companies Chronic Spontaneous Urticaria Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Chronic Spontaneous Urticaria Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
  5.2.1 Antihistamine
  5.2.2 Monoclonal Antibody
  5.2.3 Other
5.3 Market Segment by Type
  5.3.1 World Chronic Spontaneous Urticaria Market Size by Type (2018-2023)
  5.3.2 World Chronic Spontaneous Urticaria Market Size by Type (2024-2029)
  5.3.3 World Chronic Spontaneous Urticaria Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Chronic Spontaneous Urticaria Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
  6.2.1 Children
  6.2.2 Adult
6.3 Market Segment by Application
  6.3.1 World Chronic Spontaneous Urticaria Market Size by Application (2018-2023)
  6.3.2 World Chronic Spontaneous Urticaria Market Size by Application (2024-2029)
  6.3.3 World Chronic Spontaneous Urticaria Market Size by Application (2018-2029)

7 COMPANY PROFILES

7.1 Mylan N. V.
  7.1.1 Mylan N. V. Details
  7.1.2 Mylan N. V. Major Business
  7.1.3 Mylan N. V. Chronic Spontaneous Urticaria Product and Services
  7.1.4 Mylan N. V. Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.1.5 Mylan N. V. Recent Developments/Updates
  7.1.6 Mylan N. V. Competitive Strengths & Weaknesses
7.2 Sanofi
  7.2.1 Sanofi Details
  7.2.2 Sanofi Major Business
  7.2.3 Sanofi Chronic Spontaneous Urticaria Product and Services
  7.2.4 Sanofi Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.2.5 Sanofi Recent Developments/Updates
  7.2.6 Sanofi Competitive Strengths & Weaknesses
7.3 GlaxoSmithKline
  7.3.1 GlaxoSmithKline Details
  7.3.2 GlaxoSmithKline Major Business
  7.3.3 GlaxoSmithKline Chronic Spontaneous Urticaria Product and Services
  7.3.4 GlaxoSmithKline Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.3.5 GlaxoSmithKline Recent Developments/Updates
  7.3.6 GlaxoSmithKline Competitive Strengths & Weaknesses
7.4 Bayer
  7.4.1 Bayer Details
  7.4.2 Bayer Major Business
  7.4.3 Bayer Chronic Spontaneous Urticaria Product and Services
  7.4.4 Bayer Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.4.5 Bayer Recent Developments/Updates
  7.4.6 Bayer Competitive Strengths & Weaknesses
7.5 Merck
  7.5.1 Merck Details
  7.5.2 Merck Major Business
  7.5.3 Merck Chronic Spontaneous Urticaria Product and Services
  7.5.4 Merck Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.5.5 Merck Recent Developments/Updates
  7.5.6 Merck Competitive Strengths & Weaknesses
7.6 Aurobindo Pharma
  7.6.1 Aurobindo Pharma Details
  7.6.2 Aurobindo Pharma Major Business
  7.6.3 Aurobindo Pharma Chronic Spontaneous Urticaria Product and Services
  7.6.4 Aurobindo Pharma Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.6.5 Aurobindo Pharma Recent Developments/Updates
  7.6.6 Aurobindo Pharma Competitive Strengths & Weaknesses
7.7 Hikma Pharmaceuticals
  7.7.1 Hikma Pharmaceuticals Details
  7.7.2 Hikma Pharmaceuticals Major Business
  7.7.3 Hikma Pharmaceuticals Chronic Spontaneous Urticaria Product and Services
  7.7.4 Hikma Pharmaceuticals Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.7.5 Hikma Pharmaceuticals Recent Developments/Updates
  7.7.6 Hikma Pharmaceuticals Competitive Strengths & Weaknesses
7.8 WOCKHARDT
  7.8.1 WOCKHARDT Details
  7.8.2 WOCKHARDT Major Business
  7.8.3 WOCKHARDT Chronic Spontaneous Urticaria Product and Services
  7.8.4 WOCKHARDT Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.8.5 WOCKHARDT Recent Developments/Updates
  7.8.6 WOCKHARDT Competitive Strengths & Weaknesses
7.9 AbbVie, Inc.
  7.9.1 AbbVie, Inc. Details
  7.9.2 AbbVie, Inc. Major Business
  7.9.3 AbbVie, Inc. Chronic Spontaneous Urticaria Product and Services
  7.9.4 AbbVie, Inc. Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.9.5 AbbVie, Inc. Recent Developments/Updates
  7.9.6 AbbVie, Inc. Competitive Strengths & Weaknesses
7.10 Cipla Inc.
  7.10.1 Cipla Inc. Details
  7.10.2 Cipla Inc. Major Business
  7.10.3 Cipla Inc. Chronic Spontaneous Urticaria Product and Services
  7.10.4 Cipla Inc. Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.10.5 Cipla Inc. Recent Developments/Updates
  7.10.6 Cipla Inc. Competitive Strengths & Weaknesses
7.11 F. Hoffmann La Roche Ltd.
  7.11.1 F. Hoffmann La Roche Ltd. Details
  7.11.2 F. Hoffmann La Roche Ltd. Major Business
  7.11.3 F. Hoffmann La Roche Ltd. Chronic Spontaneous Urticaria Product and Services
  7.11.4 F. Hoffmann La Roche Ltd. Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.11.5 F. Hoffmann La Roche Ltd. Recent Developments/Updates
  7.11.6 F. Hoffmann La Roche Ltd. Competitive Strengths & Weaknesses
7.12 Teva Pharmaceutical Industries, Ltd.
  7.12.1 Teva Pharmaceutical Industries, Ltd. Details
  7.12.2 Teva Pharmaceutical Industries, Ltd. Major Business
  7.12.3 Teva Pharmaceutical Industries, Ltd. Chronic Spontaneous Urticaria Product and Services
  7.12.4 Teva Pharmaceutical Industries, Ltd. Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.12.5 Teva Pharmaceutical Industries, Ltd. Recent Developments/Updates
  7.12.6 Teva Pharmaceutical Industries, Ltd. Competitive Strengths & Weaknesses
7.13 Pfizer, Inc.
  7.13.1 Pfizer, Inc. Details
  7.13.2 Pfizer, Inc. Major Business
  7.13.3 Pfizer, Inc. Chronic Spontaneous Urticaria Product and Services
  7.13.4 Pfizer, Inc. Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.13.5 Pfizer, Inc. Recent Developments/Updates
  7.13.6 Pfizer, Inc. Competitive Strengths & Weaknesses
7.14 Novartis AG
  7.14.1 Novartis AG Details
  7.14.2 Novartis AG Major Business
  7.14.3 Novartis AG Chronic Spontaneous Urticaria Product and Services
  7.14.4 Novartis AG Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.14.5 Novartis AG Recent Developments/Updates
  7.14.6 Novartis AG Competitive Strengths & Weaknesses
7.15 Eli Lilly and Company
  7.15.1 Eli Lilly and Company Details
  7.15.2 Eli Lilly and Company Major Business
  7.15.3 Eli Lilly and Company Chronic Spontaneous Urticaria Product and Services
  7.15.4 Eli Lilly and Company Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.15.5 Eli Lilly and Company Recent Developments/Updates
  7.15.6 Eli Lilly and Company Competitive Strengths & Weaknesses
7.16 Allergan
  7.16.1 Allergan Details
  7.16.2 Allergan Major Business
  7.16.3 Allergan Chronic Spontaneous Urticaria Product and Services
  7.16.4 Allergan Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.16.5 Allergan Recent Developments/Updates
  7.16.6 Allergan Competitive Strengths & Weaknesses
7.17 Lupin
  7.17.1 Lupin Details
  7.17.2 Lupin Major Business
  7.17.3 Lupin Chronic Spontaneous Urticaria Product and Services
  7.17.4 Lupin Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023)
  7.17.5 Lupin Recent Developments/Updates
  7.17.6 Lupin Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

8.1 Chronic Spontaneous Urticaria Industry Chain
8.2 Chronic Spontaneous Urticaria Upstream Analysis
8.3 Chronic Spontaneous Urticaria Midstream Analysis
8.4 Chronic Spontaneous Urticaria Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Chronic Spontaneous Urticaria Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Chronic Spontaneous Urticaria Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Chronic Spontaneous Urticaria Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Chronic Spontaneous Urticaria Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Chronic Spontaneous Urticaria Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Chronic Spontaneous Urticaria Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Chronic Spontaneous Urticaria Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Chronic Spontaneous Urticaria Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Chronic Spontaneous Urticaria Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Chronic Spontaneous Urticaria Players in 2022
Table 12. World Chronic Spontaneous Urticaria Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Chronic Spontaneous Urticaria Company Evaluation Quadrant
Table 14. Head Office of Key Chronic Spontaneous Urticaria Player
Table 15. Chronic Spontaneous Urticaria Market: Company Product Type Footprint
Table 16. Chronic Spontaneous Urticaria Market: Company Product Application Footprint
Table 17. Chronic Spontaneous Urticaria Mergers & Acquisitions Activity
Table 18. United States VS China Chronic Spontaneous Urticaria Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Chronic Spontaneous Urticaria Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Chronic Spontaneous Urticaria Companies, Headquarters (States, Country)
Table 21. United States Based Companies Chronic Spontaneous Urticaria Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Chronic Spontaneous Urticaria Revenue Market Share (2018-2023)
Table 23. China Based Chronic Spontaneous Urticaria Companies, Headquarters (Province, Country)
Table 24. China Based Companies Chronic Spontaneous Urticaria Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Chronic Spontaneous Urticaria Revenue Market Share (2018-2023)
Table 26. Rest of World Based Chronic Spontaneous Urticaria Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Chronic Spontaneous Urticaria Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Chronic Spontaneous Urticaria Revenue Market Share (2018-2023)
Table 29. World Chronic Spontaneous Urticaria Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Chronic Spontaneous Urticaria Market Size by Type (2018-2023) & (USD Million)
Table 31. World Chronic Spontaneous Urticaria Market Size by Type (2024-2029) & (USD Million)
Table 32. World Chronic Spontaneous Urticaria Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Chronic Spontaneous Urticaria Market Size by Application (2018-2023) & (USD Million)
Table 34. World Chronic Spontaneous Urticaria Market Size by Application (2024-2029) & (USD Million)
Table 35. Mylan N. V. Basic Information, Area Served and Competitors
Table 36. Mylan N. V. Major Business
Table 37. Mylan N. V. Chronic Spontaneous Urticaria Product and Services
Table 38. Mylan N. V. Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Mylan N. V. Recent Developments/Updates
Table 40. Mylan N. V. Competitive Strengths & Weaknesses
Table 41. Sanofi Basic Information, Area Served and Competitors
Table 42. Sanofi Major Business
Table 43. Sanofi Chronic Spontaneous Urticaria Product and Services
Table 44. Sanofi Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Sanofi Recent Developments/Updates
Table 46. Sanofi Competitive Strengths & Weaknesses
Table 47. GlaxoSmithKline Basic Information, Area Served and Competitors
Table 48. GlaxoSmithKline Major Business
Table 49. GlaxoSmithKline Chronic Spontaneous Urticaria Product and Services
Table 50. GlaxoSmithKline Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. GlaxoSmithKline Recent Developments/Updates
Table 52. GlaxoSmithKline Competitive Strengths & Weaknesses
Table 53. Bayer Basic Information, Area Served and Competitors
Table 54. Bayer Major Business
Table 55. Bayer Chronic Spontaneous Urticaria Product and Services
Table 56. Bayer Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Bayer Recent Developments/Updates
Table 58. Bayer Competitive Strengths & Weaknesses
Table 59. Merck Basic Information, Area Served and Competitors
Table 60. Merck Major Business
Table 61. Merck Chronic Spontaneous Urticaria Product and Services
Table 62. Merck Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Merck Recent Developments/Updates
Table 64. Merck Competitive Strengths & Weaknesses
Table 65. Aurobindo Pharma Basic Information, Area Served and Competitors
Table 66. Aurobindo Pharma Major Business
Table 67. Aurobindo Pharma Chronic Spontaneous Urticaria Product and Services
Table 68. Aurobindo Pharma Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Aurobindo Pharma Recent Developments/Updates
Table 70. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 71. Hikma Pharmaceuticals Basic Information, Area Served and Competitors
Table 72. Hikma Pharmaceuticals Major Business
Table 73. Hikma Pharmaceuticals Chronic Spontaneous Urticaria Product and Services
Table 74. Hikma Pharmaceuticals Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Hikma Pharmaceuticals Recent Developments/Updates
Table 76. Hikma Pharmaceuticals Competitive Strengths & Weaknesses
Table 77. WOCKHARDT Basic Information, Area Served and Competitors
Table 78. WOCKHARDT Major Business
Table 79. WOCKHARDT Chronic Spontaneous Urticaria Product and Services
Table 80. WOCKHARDT Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. WOCKHARDT Recent Developments/Updates
Table 82. WOCKHARDT Competitive Strengths & Weaknesses
Table 83. AbbVie, Inc. Basic Information, Area Served and Competitors
Table 84. AbbVie, Inc. Major Business
Table 85. AbbVie, Inc. Chronic Spontaneous Urticaria Product and Services
Table 86. AbbVie, Inc. Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. AbbVie, Inc. Recent Developments/Updates
Table 88. AbbVie, Inc. Competitive Strengths & Weaknesses
Table 89. Cipla Inc. Basic Information, Area Served and Competitors
Table 90. Cipla Inc. Major Business
Table 91. Cipla Inc. Chronic Spontaneous Urticaria Product and Services
Table 92. Cipla Inc. Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Cipla Inc. Recent Developments/Updates
Table 94. Cipla Inc. Competitive Strengths & Weaknesses
Table 95. F. Hoffmann La Roche Ltd. Basic Information, Area Served and Competitors
Table 96. F. Hoffmann La Roche Ltd. Major Business
Table 97. F. Hoffmann La Roche Ltd. Chronic Spontaneous Urticaria Product and Services
Table 98. F. Hoffmann La Roche Ltd. Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. F. Hoffmann La Roche Ltd. Recent Developments/Updates
Table 100. F. Hoffmann La Roche Ltd. Competitive Strengths & Weaknesses
Table 101. Teva Pharmaceutical Industries, Ltd. Basic Information, Area Served and Competitors
Table 102. Teva Pharmaceutical Industries, Ltd. Major Business
Table 103. Teva Pharmaceutical Industries, Ltd. Chronic Spontaneous Urticaria Product and Services
Table 104. Teva Pharmaceutical Industries, Ltd. Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Teva Pharmaceutical Industries, Ltd. Recent Developments/Updates
Table 106. Teva Pharmaceutical Industries, Ltd. Competitive Strengths & Weaknesses
Table 107. Pfizer, Inc. Basic Information, Area Served and Competitors
Table 108. Pfizer, Inc. Major Business
Table 109. Pfizer, Inc. Chronic Spontaneous Urticaria Product and Services
Table 110. Pfizer, Inc. Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Pfizer, Inc. Recent Developments/Updates
Table 112. Pfizer, Inc. Competitive Strengths & Weaknesses
Table 113. Novartis AG Basic Information, Area Served and Competitors
Table 114. Novartis AG Major Business
Table 115. Novartis AG Chronic Spontaneous Urticaria Product and Services
Table 116. Novartis AG Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Novartis AG Recent Developments/Updates
Table 118. Novartis AG Competitive Strengths & Weaknesses
Table 119. Eli Lilly and Company Basic Information, Area Served and Competitors
Table 120. Eli Lilly and Company Major Business
Table 121. Eli Lilly and Company Chronic Spontaneous Urticaria Product and Services
Table 122. Eli Lilly and Company Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Eli Lilly and Company Recent Developments/Updates
Table 124. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 125. Allergan Basic Information, Area Served and Competitors
Table 126. Allergan Major Business
Table 127. Allergan Chronic Spontaneous Urticaria Product and Services
Table 128. Allergan Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Allergan Recent Developments/Updates
Table 130. Lupin Basic Information, Area Served and Competitors
Table 131. Lupin Major Business
Table 132. Lupin Chronic Spontaneous Urticaria Product and Services
Table 133. Lupin Chronic Spontaneous Urticaria Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 134. Global Key Players of Chronic Spontaneous Urticaria Upstream (Raw Materials)
Table 135. Chronic Spontaneous Urticaria Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Chronic Spontaneous Urticaria Picture
Figure 2. World Chronic Spontaneous Urticaria Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Chronic Spontaneous Urticaria Total Market Size (2018-2029) & (USD Million)
Figure 4. World Chronic Spontaneous Urticaria Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Chronic Spontaneous Urticaria Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Chronic Spontaneous Urticaria Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Chronic Spontaneous Urticaria Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Chronic Spontaneous Urticaria Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Chronic Spontaneous Urticaria Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Chronic Spontaneous Urticaria Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Chronic Spontaneous Urticaria Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Chronic Spontaneous Urticaria Revenue (2018-2029) & (USD Million)
Figure 13. Chronic Spontaneous Urticaria Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Chronic Spontaneous Urticaria Consumption Value (2018-2029) & (USD Million)
Figure 16. World Chronic Spontaneous Urticaria Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Chronic Spontaneous Urticaria Consumption Value (2018-2029) & (USD Million)
Figure 18. China Chronic Spontaneous Urticaria Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Chronic Spontaneous Urticaria Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Chronic Spontaneous Urticaria Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Chronic Spontaneous Urticaria Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Chronic Spontaneous Urticaria Consumption Value (2018-2029) & (USD Million)
Figure 23. India Chronic Spontaneous Urticaria Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Chronic Spontaneous Urticaria by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Chronic Spontaneous Urticaria Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Chronic Spontaneous Urticaria Markets in 2022
Figure 27. United States VS China: Chronic Spontaneous Urticaria Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Chronic Spontaneous Urticaria Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Chronic Spontaneous Urticaria Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Chronic Spontaneous Urticaria Market Size Market Share by Type in 2022
Figure 31. Antihistamine
Figure 32. Monoclonal Antibody
Figure 33. Other
Figure 34. World Chronic Spontaneous Urticaria Market Size Market Share by Type (2018-2029)
Figure 35. World Chronic Spontaneous Urticaria Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Chronic Spontaneous Urticaria Market Size Market Share by Application in 2022
Figure 37. Children
Figure 38. Adult
Figure 39. Chronic Spontaneous Urticaria Industrial Chain
Figure 40. Methodology
Figure 41. Research Process and Data Source